Association between vitamin D receptor gene polymorphism and cardiomyopathy in response to adriamycin treatment among breast cancer patients

Abstract

Abstract Background Chemotherapy-induced cardiomyopathy (CIC) is a common side effect affecting patients with breast cancer treated with anthracyclines chemotherapeutic agents. Vitamin D receptor gene polymorphism seemed to play a crucial role in developing CIC, as vitamin D deficiency was found to increase the risk of many diseases including colon, breast, prostate and ovarian cancer. Purpose The current study is primarily to investigate the effect of vitamin D receptor gene polymorphism (ApaI, TaqI, BsmI and FokI) on the incidence of CIC in adult patients with local/advanced or metastatic breast cancer on anthracyclines. Another aim is to detect the association of the gene polymorphism with the response to treatment with chemotherapeutic agents. Moreover, the current study investigated the expression of miR-155 in patients and analyzed its relationship with CIC occurrence. Methods This case-control study recruited 60 breast cancer patients with CIC and 30 breast cancer patients without CIC from cardiology and oncology clinics between February 2017 and November 2021. Genomic DNA was extracted from peripheral blood samples and VDR gene polymorphisms were detected using TaqMan techniques. Results For the ApaI (rs7975232) and TaqI (rs731236) single-nucleotide polymorphisms (SNPs), the heterozygous (CA) and heterozygous (GA) genotypes increased the risk of CIC among breast cancer patients compared to the control group (OR = 4.31, P < 0.001; OR = 3.2, P = 0.015, respectively). In contrast, homozygous (CC) carriers of the BsmI SNP (rs1544410) had a significantly lower risk for CIC among breast cancer patients (P < 0.001). Finally, for the FokI SNP (rs2228570), there was no significant association with CIC risk. Levels of miR-155 were significantly increased in CIC group compared to the control group (P = 0.015). Conclusion The C allele carriers of ApaI SNP and A allele carriers of TaqI SNP are at higher risk of CIC among breast cancer patients; in contrast, the homozygous (CC) carriers of the BsmI SNP are protective against CIC among breast cancer patients. Additionally, higher levels of miR-155 are associated with CIC increased risk among breast cancer patients.